Rap Surgicals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-07-2024
- Paid Up Capital ₹ 0.90 M
as on 05-07-2024
- Company Age 20 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 58.42 Cr
as on 05-07-2024
- Revenue %
(FY 2022)
- Profit -16.13%
(FY 2022)
- Ebitda -16.13%
(FY 2022)
- Net Worth -0.14%
(FY 2022)
- Total Assets -0.14%
(FY 2022)
About Rap Surgicals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹58.42 Cr.
Vikash Swaroop and Saurabh Bansal serve as directors at the Company.
- CIN/LLPIN
U24236UP2003PTC028175
- Company No.
028175
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Dec 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Uttar Pradesh, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rap Surgicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikash Swaroop  | Director | 01-Jun-2012 | Current |
| Saurabh Bansal | Director | 01-Jun-2012 | Current |
Financial Performance of Rap Surgicals.
Rap Surgicals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 16.13% decrease in profit. The company's net worth dipped by a decrease of 0.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rap Surgicals?
In 2021, Rap Surgicals had a promoter holding of 11.11% and a public holding of 88.89%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Swarup Beverages Private LimitedActive 20 years 9 monthsVikash Swaroop and Saurabh Bansal are mutual person
- Swarup Iron & Steels Private LimitedActive 14 years 6 months
Vikash Swaroop and Saurabh Bansal are mutual person
- Swarup Steel Industries Private LimitedActive 5 years 1 month
Vikash Swaroop and Saurabh Bansal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 Apr 2020 | ₹47.32 Cr | Open |
Others Creation Date: 26 Dec 2016 | ₹11.10 Cr | Open |
How Many Employees Work at Rap Surgicals?
Unlock and access historical data on people associated with Rap Surgicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rap Surgicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rap Surgicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
